Skip to content

Comparison between three drugs for treatment of patients with sudden vision loss due to reduced blood flow to optic nerve to evaluate improvement in visual acuity and decide best treatment

Comparative study between Oral steroids, Intravitreal Triamcinolone and Intravitreal Ranibizumab for Non- Arteritic Anterior Ischemic Optic Neuropathy - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094818
Enrollment
30
Registered
2025-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H470- Disorders of optic nerve, not elsewhere classified

Interventions

Intervention1: Oral Prednisolone tablet(Wysolone): starting on 1 mg per kg Prednisone loading dose which will be tapering down by 10mg every 5 days Control Intervention1: Intravitreal Traimcinolone Ac

Sponsors

Dr Shrutika Laxmikant Pokale
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All diagnosed cases of NA-AION, presenting with - A history of sudden painless visual loss and an absence of other ocular, systemic or neurological diseases that might influence or explain the patient s visual symptoms, with Optic disc edema (ODE) RNFL thickness more than 120 measured by spectral domain OCT HFA (30-2 programme)showing altitudinal visual field defect No history of neurologic, systemic or ocular disorder, which could be responsible for ODE and visual impairment must be present. The patient must not have had any treatment for NA-AION prior to our evaluation, There must be a follow-up of 3 months at least to provide enough length of follow-up to obtain valid information in the three treated groups

Exclusion criteria

Exclusion criteria: Patients who had any retinal or optic nerve lesion (Glaucoma/ Vascular diseases or Uveitis) or any other factor (e.g. cataract) which could influence the visual status. NA-AION patients with only background diabetic retinopathy will be included, but those who has active neovascularization, vitreous hemorrhages, traction detachment, DME or other complications influencing the visual acuity or fields will be excluded. Patients who had a diagnosis of glaucoma and visual field loss are excluded; however, those with history of elevated intraocular pressure and on ocular hypotensive therapy, with a documented normal field prior to the onset of NA-AION, are included. Patients with a follow-up of less than 3 months are excluded.

Design outcomes

Primary

MeasureTime frame
Visual acuity by LogMAR chartTimepoint: 1week,1 month,3month

Secondary

MeasureTime frame
Visual fields by HFATimepoint: 1week,1month,3months;Mean RNFL thickness on OCTTimepoint: 1week,1month,3months

Countries

India

Contacts

Public ContactDr Ashok Kanakamedala

Sankara Eye Hospital,Guntur

dr.ashok83@gmail.com7799444282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026